Advances of Electrochemical Biosensors for the Detection of Oncological Disease

A special issue of Biosensors (ISSN 2079-6374). This special issue belongs to the section "Biosensors and Healthcare".

Deadline for manuscript submissions: closed (15 December 2021) | Viewed by 3161

Special Issue Editors

Food Quality and Safety Group, International Iberian Nanotechnology Laboratory (INL), Av. Mestre José Veiga, 4715-330 Braga, Portugal
Interests: surface functionalization; electrochemical biosensors; assay development; new materials for biosensor development
Special Issues, Collections and Topics in MDPI journals
Centre for Microsystems Technology, ELIS Department, Ghent University, Technologiepark-Zwijnaarde 126 (iGent building, 6th floor), 9052 Gent, Belgium
Interests: electrochemical biosensors; immunosensors; immunoassay; biomarker detection; POC devices; diagnosis

Special Issue Information

Dear Colleagues,

Cancer is the second most common cause of death worldwide, with nearly 10 million deaths registered in 2018. The disease represents a high burden physically, psychologically and financially on individuals, families, communities and health systems. Earlier detection and continuous monitoring can lead to a decrease in the death rate and an increase in the quality of life of the patients. Imaging techniques give the location and size of the tumour, but for the diagnosis and design of a personalised treatment plan, it is necessary to sample. Tissue biopsy is the gold standard but second biopsies are avoided since they present high risk to the patient and conventional pathology techniques cannot extract useful information from them. Analysis of bodily fluids opens the possibility to collect repeated samples and track biomarkers levels throughout the course of the disease and during treatment. This allows clinical decisions to be made, using real-time biopsy and treatment strategies to be adapted each time there is a change from drug sensitive to drug resistant disease, leading to personalised medicine and higher success rate treatment.

In this Special Issue, we will focus on various electrochemical sensor and biosensor platforms for the detection of cancer biomarkers. We seek unique research and development efforts, identifying novel sensing platforms for the detection of cancer biomarkers towards clinical applications.

Dr. Rui Campos
Dr. Paula Lopes
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biosensors is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biosensor
  • point-of-care
  • cancer screening

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3065 KiB  
Article
Reverse Electrochemical Sensing of FLT3-ITD Mutations in Acute Myeloid Leukemia Using Gold Sputtered ZnO-Nanorod Configured DNA Biosensors
by Ramesh Thevendran, Kai Loong Foo, Mohd Hazwan Hussin, Emmanuel Jairaj Moses, Marimuthu Citartan, Haarindraprasad Rajintra Prasad and Solayappan Maheswaran
Biosensors 2022, 12(3), 170; https://0-doi-org.brum.beds.ac.uk/10.3390/bios12030170 - 10 Mar 2022
Cited by 3 | Viewed by 2587
Abstract
Detection of genetic mutations leading to hematological malignancies is a key factor in the early diagnosis of acute myeloid leukemia (AML). FLT3-ITD mutations are an alarming gene defect found commonly in AML patients associated with high cases of leukemia and low survival rates. [...] Read more.
Detection of genetic mutations leading to hematological malignancies is a key factor in the early diagnosis of acute myeloid leukemia (AML). FLT3-ITD mutations are an alarming gene defect found commonly in AML patients associated with high cases of leukemia and low survival rates. Available diagnostic assessments for FLT3-ITD are incapable of combining cost-effective detection platforms with high analytical performances. To circumvent this, we developed an efficient DNA biosensor for the recognition of AML caused by FLT3-ITD mutation utilizing electrochemical impedance characterization. The system was designed by adhering gold-sputtered zinc oxide (ZnO) nanorods onto interdigitated electrode (IDE) sensor chips. The sensing surface was biointerfaced with capture probes designed to hybridize with unmutated FLT3 sequences instead of the mutated FLT3-ITD gene, establishing a reverse manner of target detection. The developed biosensor demonstrated specific detection of mutated FLT3 genes, with high levels of sensitivity in response to analyte concentrations as low as 1 nM. The sensor also exhibited a stable functional life span of more than five weeks with good reproducibility and high discriminatory properties against FLT3 gene targets. Hence, the developed sensor is a promising tool for rapid and low-cost diagnostic applications relevant to the clinical prognosis of AML stemming from FLT3-ITD mutations. Full article
Show Figures

Figure 1

Back to TopTop